Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 26.5
(-3.21%)
USD 26.5
(-3.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.6 Billion USD | 32.76% |
| 2022 | 1.96 Billion USD | 6.58% |
| 2021 | 1.84 Billion USD | 18.94% |
| 2020 | 1.54 Billion USD | -0.06% |
| 2019 | 1.54 Billion USD | 4.55% |
| 2018 | 1.48 Billion USD | 63.91% |
| 2017 | 903.3 Million USD | 11.12% |
| 2016 | 812.9 Million USD | 7.62% |
| 2015 | 755.31 Million USD | 8.21% |
| 2014 | 698.02 Million USD | 48.91% |
| 2013 | 468.76 Million USD | 29.17% |
| 2012 | 362.92 Million USD | 15.78% |
| 2011 | 313.46 Million USD | 2.46% |
| 2010 | 305.93 Million USD | -13.85% |
| 2009 | 355.11 Million USD | -24.43% |
| 2008 | 469.9 Million USD | 89.01% |
| 2007 | 248.61 Million USD | 57.35% |
| 2006 | 158 Million USD | -3.48% |
| 2005 | 163.7 Million USD | -41.65% |
| 2004 | 280.55 Million USD | 4.78% |
| 2003 | 267.76 Million USD | -5.45% |
| 2002 | 283.2 Million USD | 46.01% |
| 2001 | 193.96 Million USD | 65.94% |
| 2000 | 116.89 Million USD | 14.26% |
| 1999 | 102.3 Million USD | 1.99% |
| 1998 | 100.3 Million USD | 20.84% |
| 1997 | 83 Million USD | 93.47% |
| 1996 | 42.9 Million USD | 81.01% |
| 1995 | 23.7 Million USD | 15.05% |
| 1994 | 20.6 Million USD | 1.48% |
| 1993 | 20.3 Million USD | 29.3% |
| 1992 | 15.7 Million USD | 8.28% |
| 1991 | 14.5 Million USD | 457.69% |
| 1990 | 2.6 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.42 Billion USD | -1.62% |
| 2024 Q1 | 2.46 Billion USD | -5.22% |
| 2023 Q2 | 2.54 Billion USD | 6.05% |
| 2023 FY | 2.6 Billion USD | 32.76% |
| 2023 Q3 | 2.61 Billion USD | 2.99% |
| 2023 Q4 | 2.6 Billion USD | -0.6% |
| 2023 Q1 | 2.39 Billion USD | 22.28% |
| 2022 Q2 | 1.83 Billion USD | 1.21% |
| 2022 FY | 1.96 Billion USD | 6.58% |
| 2022 Q1 | 1.8 Billion USD | -1.66% |
| 2022 Q4 | 1.96 Billion USD | 7.3% |
| 2022 Q3 | 1.82 Billion USD | -0.21% |
| 2021 FY | 1.84 Billion USD | 18.94% |
| 2021 Q1 | 1.56 Billion USD | 1.36% |
| 2021 Q4 | 1.84 Billion USD | -2.35% |
| 2021 Q2 | 1.91 Billion USD | 22.09% |
| 2021 Q3 | 1.88 Billion USD | -1.57% |
| 2020 Q4 | 1.54 Billion USD | 3.87% |
| 2020 Q1 | 1.52 Billion USD | -1.78% |
| 2020 FY | 1.54 Billion USD | -0.06% |
| 2020 Q2 | 1.48 Billion USD | -2.39% |
| 2020 Q3 | 1.48 Billion USD | 0.35% |
| 2019 Q2 | 1.42 Billion USD | -1.9% |
| 2019 Q3 | 1.39 Billion USD | -1.69% |
| 2019 Q4 | 1.54 Billion USD | 10.81% |
| 2019 FY | 1.54 Billion USD | 4.55% |
| 2019 Q1 | 1.44 Billion USD | -2.17% |
| 2018 Q3 | 1.4 Billion USD | -1.55% |
| 2018 Q4 | 1.48 Billion USD | 5.18% |
| 2018 FY | 1.48 Billion USD | 63.91% |
| 2018 Q1 | 912.45 Million USD | 1.01% |
| 2018 Q2 | 1.42 Billion USD | 56.71% |
| 2017 Q2 | 875.26 Million USD | -0.79% |
| 2017 Q3 | 854.89 Million USD | -2.33% |
| 2017 Q4 | 903.3 Million USD | 5.66% |
| 2017 FY | 903.3 Million USD | 11.12% |
| 2017 Q1 | 882.19 Million USD | 8.52% |
| 2016 Q4 | 812.9 Million USD | 15.48% |
| 2016 FY | 812.9 Million USD | 7.62% |
| 2016 Q1 | 717.65 Million USD | -4.99% |
| 2016 Q2 | 699.89 Million USD | -2.47% |
| 2016 Q3 | 703.94 Million USD | 0.58% |
| 2015 Q3 | 742.59 Million USD | 9.86% |
| 2015 Q4 | 755.31 Million USD | 1.71% |
| 2015 Q1 | 679.58 Million USD | -2.64% |
| 2015 FY | 755.31 Million USD | 8.21% |
| 2015 Q2 | 675.93 Million USD | -0.54% |
| 2014 Q3 | 449.03 Million USD | -0.42% |
| 2014 Q2 | 450.91 Million USD | -2.08% |
| 2014 Q1 | 460.51 Million USD | -1.76% |
| 2014 FY | 698.02 Million USD | 48.91% |
| 2014 Q4 | 698.02 Million USD | 55.45% |
| 2013 Q4 | 468.76 Million USD | -2.44% |
| 2013 Q2 | 387.57 Million USD | 10.15% |
| 2013 Q1 | 351.87 Million USD | -3.04% |
| 2013 FY | 468.76 Million USD | 29.17% |
| 2013 Q3 | 480.47 Million USD | 23.97% |
| 2012 Q1 | 319.93 Million USD | 2.07% |
| 2012 Q3 | 315.4 Million USD | -0.84% |
| 2012 Q4 | 362.92 Million USD | 15.07% |
| 2012 Q2 | 318.08 Million USD | -0.58% |
| 2012 FY | 362.92 Million USD | 15.78% |
| 2011 Q1 | 278.23 Million USD | -9.05% |
| 2011 FY | 313.46 Million USD | 2.46% |
| 2011 Q3 | 318.96 Million USD | 0.51% |
| 2011 Q2 | 317.35 Million USD | 14.06% |
| 2011 Q4 | 313.46 Million USD | -1.72% |
| 2010 Q3 | 322.14 Million USD | -6.39% |
| 2010 Q2 | 344.12 Million USD | 9.15% |
| 2010 Q1 | 315.28 Million USD | -11.22% |
| 2010 FY | 305.93 Million USD | -13.85% |
| 2010 Q4 | 305.93 Million USD | -5.03% |
| 2009 Q3 | 375.75 Million USD | -6.84% |
| 2009 Q1 | 421.83 Million USD | -10.23% |
| 2009 FY | 355.11 Million USD | -24.43% |
| 2009 Q2 | 403.34 Million USD | -4.38% |
| 2009 Q4 | 355.11 Million USD | -5.49% |
| 2008 Q3 | 476.94 Million USD | -6.34% |
| 2008 Q4 | 469.9 Million USD | -1.48% |
| 2008 FY | 469.9 Million USD | 89.01% |
| 2008 Q1 | 327.94 Million USD | 31.91% |
| 2008 Q2 | 509.22 Million USD | 55.28% |
| 2007 FY | 248.61 Million USD | 57.35% |
| 2007 Q1 | 270.47 Million USD | 71.18% |
| 2007 Q2 | 201.04 Million USD | -25.67% |
| 2007 Q3 | 202.81 Million USD | 0.88% |
| 2007 Q4 | 248.61 Million USD | 22.58% |
| 2006 FY | 158 Million USD | -3.48% |
| 2006 Q1 | 158.78 Million USD | -3.01% |
| 2006 Q2 | 156.45 Million USD | -1.47% |
| 2006 Q3 | 154.17 Million USD | -1.46% |
| 2006 Q4 | 158 Million USD | 2.49% |
| 2005 Q4 | 163.7 Million USD | -5.56% |
| 2005 Q3 | 173.34 Million USD | -35.97% |
| 2005 Q2 | 270.71 Million USD | -3.25% |
| 2005 Q1 | 279.79 Million USD | -0.27% |
| 2005 FY | 163.7 Million USD | -41.65% |
| 2004 Q4 | 280.55 Million USD | 2.8% |
| 2004 FY | 280.55 Million USD | 4.78% |
| 2004 Q3 | 272.91 Million USD | 1.7% |
| 2004 Q2 | 268.35 Million USD | 1.2% |
| 2004 Q1 | 265.17 Million USD | -0.97% |
| 2003 Q2 | 258.02 Million USD | -8.12% |
| 2003 Q3 | 260.03 Million USD | 0.78% |
| 2003 FY | 267.76 Million USD | -5.45% |
| 2003 Q1 | 280.82 Million USD | -0.84% |
| 2003 Q4 | 267.76 Million USD | 2.97% |
| 2002 Q2 | 256.85 Million USD | 30.55% |
| 2002 Q1 | 196.75 Million USD | 1.44% |
| 2002 FY | 283.2 Million USD | 46.01% |
| 2002 Q4 | 283.2 Million USD | 11.52% |
| 2002 Q3 | 253.95 Million USD | -1.13% |
| 2001 Q1 | 118.89 Million USD | 1.72% |
| 2001 Q4 | 193.96 Million USD | 9.97% |
| 2001 Q3 | 176.38 Million USD | 24.56% |
| 2001 Q2 | 141.6 Million USD | 19.1% |
| 2001 FY | 193.96 Million USD | 65.94% |
| 2000 Q3 | 110.61 Million USD | 3.12% |
| 2000 FY | 116.89 Million USD | 14.26% |
| 2000 Q2 | 107.26 Million USD | 3.18% |
| 2000 Q1 | 103.95 Million USD | 1.62% |
| 2000 Q4 | 116.89 Million USD | 5.68% |
| 1999 Q1 | 98.6 Million USD | -1.69% |
| 1999 Q4 | 102.3 Million USD | -1.06% |
| 1999 FY | 102.3 Million USD | 1.99% |
| 1999 Q3 | 103.4 Million USD | 2.89% |
| 1999 Q2 | 100.5 Million USD | 1.93% |
| 1998 FY | 100.3 Million USD | 20.84% |
| 1998 Q4 | 100.3 Million USD | 5.69% |
| 1998 Q3 | 94.9 Million USD | -9.53% |
| 1998 Q2 | 104.9 Million USD | 36.77% |
| 1998 Q1 | 76.7 Million USD | -7.59% |
| 1997 Q3 | 55.9 Million USD | -2.1% |
| 1997 FY | 83 Million USD | 93.47% |
| 1997 Q1 | 46.8 Million USD | 9.09% |
| 1997 Q4 | 83 Million USD | 48.48% |
| 1997 Q2 | 57.1 Million USD | 22.01% |
| 1996 FY | 42.9 Million USD | 81.01% |
| 1996 Q4 | 42.9 Million USD | 72.29% |
| 1996 Q1 | 27.2 Million USD | 14.77% |
| 1996 Q2 | 25.8 Million USD | -5.15% |
| 1996 Q3 | 24.9 Million USD | -3.49% |
| 1995 Q3 | 26.9 Million USD | 32.51% |
| 1995 Q1 | 19.7 Million USD | -4.37% |
| 1995 Q4 | 23.7 Million USD | -11.9% |
| 1995 FY | 23.7 Million USD | 15.05% |
| 1995 Q2 | 20.3 Million USD | 3.05% |
| 1994 FY | 20.6 Million USD | 1.48% |
| 1994 Q1 | 17.2 Million USD | -15.27% |
| 1994 Q3 | 19.4 Million USD | 16.87% |
| 1994 Q4 | 20.6 Million USD | 6.19% |
| 1994 Q2 | 16.6 Million USD | -3.49% |
| 1993 FY | 20.3 Million USD | 29.3% |
| 1993 Q1 | 14.3 Million USD | -8.92% |
| 1993 Q2 | 14.2 Million USD | -0.7% |
| 1993 Q3 | 16.7 Million USD | 17.61% |
| 1993 Q4 | 20.3 Million USD | 21.56% |
| 1992 FY | 15.7 Million USD | 8.28% |
| 1992 Q4 | 15.7 Million USD | 0.64% |
| 1992 Q1 | 14.4 Million USD | -0.69% |
| 1992 Q2 | 15.1 Million USD | 4.86% |
| 1992 Q3 | 15.6 Million USD | 3.31% |
| 1991 Q1 | 6.2 Million USD | 138.46% |
| 1991 Q4 | 14.5 Million USD | 55.91% |
| 1991 FY | 14.5 Million USD | 457.69% |
| 1991 Q3 | 9.3 Million USD | -7.92% |
| 1991 Q2 | 10.1 Million USD | 62.9% |
| 1990 Q4 | 2.6 Million USD | 0.0% |
| 1990 FY | 2.6 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -317.197% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1964.557% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -321.46% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -883.393% |
| bluebird bio, Inc. | 424.62 Million USD | -513.104% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -3686.248% |
| Imunon, Inc. | 8.53 Million USD | -30418.824% |
| Editas Medicine, Inc. | 150.05 Million USD | -1634.943% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 87.343% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 25.734% |
| Myriad Genetics, Inc. | 312.9 Million USD | -732.019% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -155.384% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -434.071% |
| Verastem, Inc. | 71.18 Million USD | -3557.211% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 96.219% |
| Waters Corporation | 3.47 Billion USD | 25.115% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 94.982% |
| Biogen Inc. | 12.04 Billion USD | 78.387% |
| Nektar Therapeutics | 267.04 Million USD | -874.883% |
| Perrigo Company plc | 6.04 Billion USD | 56.906% |
| Dynavax Technologies Corporation | 375.02 Million USD | -594.192% |
| Illumina, Inc. | 4.36 Billion USD | 40.371% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -7300.795% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1230.036% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -915.048% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -6881.084% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -37.741% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -3058.184% |
| Evolus, Inc. | 209.68 Million USD | -1141.558% |
| Adicet Bio, Inc. | 37.12 Million USD | -6913.432% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -6371.899% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 63.369% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -293.981% |
| FibroGen, Inc. | 585.72 Million USD | -344.47% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 47.064% |
| OPKO Health, Inc. | 622.47 Million USD | -318.229% |
| Homology Medicines, Inc. | 118.53 Million USD | -2096.339% |
| Geron Corporation | 146.12 Million USD | -1681.591% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 35.727% |
| Exelixis, Inc. | 678.44 Million USD | -283.728% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -12870.883% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -20670.592% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -938.0% |
| Zoetis Inc. | 9.29 Billion USD | 71.992% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -555.337% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -5194.017% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 49.447% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -5273.9% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -8.238% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -2167.521% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -57.832% |
| Blueprint Medicines Corporation | 918.64 Million USD | -183.395% |
| Insmed Incorporated | 1.66 Billion USD | -56.664% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1439.691% |
| Incyte Corporation | 1.59 Billion USD | -63.502% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -119.584% |